At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
NRXP NRX Pharmaceuticals Inc.
Pre-Mkt 11-04 05:48:46 EST
2.24
+0.07
+3.23%
盘前2.29
+0.05+2.33%
05:11 EST
High2.34Low2.11Vol1.80M
Open2.17D1 Closing2.17Amplitude10.60%
Mkt Cap96.98MTradable Cap83.82MTotal Shares43.30M
T/O3.98MT/O Rate4.81%Tradable Shares37.42M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

NRX Pharmaceuticals is Maintained at Buy by Ascendiant Capital
Dow Jones  ·  11-02 17:57
NRX Pharmaceuticals is Maintained at Buy by Ascendiant Capital
NRX Pharmaceuticals (NRXP) Receives a Buy from BTIG
TIPRANKS  ·  11-02 09:35
NRX Pharmaceuticals (NRXP) Receives a Buy from BTIG
U.S. Stocks on the MOVE-Chevron, Regeneron, ExxonMobil
Reuters  ·  10-30
U.S. Stocks on the MOVE-Chevron, Regeneron, ExxonMobil
NRx Pharma Rises After FDA Approves Preservative-Free Ketamine Injection
Reuters  ·  10-30
NRx Pharma Rises After FDA Approves Preservative-Free Ketamine Injection
NRX Pharmaceuticals - to Manufacture Sterile Injectable Drugs in U.S. with Nephron Pharmaceuticals
THOMSON REUTERS  ·  10-30
NRX Pharmaceuticals - to Manufacture Sterile Injectable Drugs in U.S. with Nephron Pharmaceuticals
NRX Pharmaceuticals (Nasdaq:Nrxp) Receives FDA Approval of Preservative-Free Ketamine Ahead of November 10 FDA Goal Date
THOMSON REUTERS  ·  10-30
NRX Pharmaceuticals (Nasdaq:Nrxp) Receives FDA Approval of Preservative-Free Ketamine Ahead of November 10 FDA Goal Date
NRx Pharmaceuticals (Nasdaq: NRXP) to Host Conference Call on October 30, 2026 to Discuss Regulatory Milestone for Preservative-Free Ketamine
GlobeNewswire  ·  10-30
NRx Pharmaceuticals (Nasdaq: NRXP) to Host Conference Call on October 30, 2026 to Discuss Regulatory Milestone for Preservative-Free Ketamine
NRx Pharmaceuticals says NY Times retracts ‘false statements’ about NRx
TIPRANKS  ·  10-24
NRx Pharmaceuticals says NY Times retracts ‘false statements’ about NRx
NRx Pharmaceuticals calls NY Times report ‘knowingly false,’ demands retraction
TIPRANKS  ·  10-22
NRx Pharmaceuticals calls NY Times report ‘knowingly false,’ demands retraction
NRx Pharmaceuticals’ Ketafree leads FDA approval race, NY Times reports
TIPRANKS  ·  10-20
NRx Pharmaceuticals’ Ketafree leads FDA approval race, NY Times reports
NRx Pharmaceuticals Completes Manufacturing Validation for Preservative-Free Ketamine
Reuters  ·  10-19
NRx Pharmaceuticals Completes Manufacturing Validation for Preservative-Free Ketamine
NRX Pharmaceuticals Announces Annual Shareholder Meeting
Reuters  ·  10-17
NRX Pharmaceuticals Announces Annual Shareholder Meeting
NRX Pharmaceuticals - Requested to Submit Labels with Proprietary Name Under FDA Review
THOMSON REUTERS  ·  10-15
NRX Pharmaceuticals - Requested to Submit Labels with Proprietary Name Under FDA Review
NRX Pharmaceuticals - All Requested Changes Classified as "Minor" Before Nov 10, 2026 Gdufa Goal Date
THOMSON REUTERS  ·  10-15
NRX Pharmaceuticals - All Requested Changes Classified as "Minor" Before Nov 10, 2026 Gdufa Goal Date
NRX Pharmaceuticals Announces Receipt of FDA Labeling Review Letter for Preservative-Free Ketamine
THOMSON REUTERS  ·  10-15
NRX Pharmaceuticals Announces Receipt of FDA Labeling Review Letter for Preservative-Free Ketamine
NRx Defense Systems Wins Initial $11.18 Million DARPA Prime Contract for SPARC-TMS Depression Trial
Reuters  ·  10-06
NRx Defense Systems Wins Initial $11.18 Million DARPA Prime Contract for SPARC-TMS Depression Trial
NRX Pharmaceuticals is Maintained at Buy by Ascendiant Capital
Dow Jones  ·  10-01
NRX Pharmaceuticals is Maintained at Buy by Ascendiant Capital
NRx Defense Systems, NRX Pharma Unit, Wins $11.18 Million DARPA Contract for Depression Treatment Trial
Reuters  ·  09-30
NRx Defense Systems, NRX Pharma Unit, Wins $11.18 Million DARPA Contract for Depression Treatment Trial
NRX Defense Systems, an NRX Company (Nasdaq:Nrxp) Awarded $11 Million Dollar Darpa Prime Contract to Evaluate Robotic Magnetic Stimulation in Conjunction with NRX-101 for Treatment of Resistant Depression
THOMSON REUTERS  ·  09-30
NRX Defense Systems, an NRX Company (Nasdaq:Nrxp) Awarded $11 Million Dollar Darpa Prime Contract to Evaluate Robotic Magnetic Stimulation in Conjunction with NRX-101 for Treatment of Resistant Depression
NRX Pharmaceuticals (NRXP) Receives a Rating Update from a Top Analyst
TIPRANKS  ·  09-22
NRX Pharmaceuticals (NRXP) Receives a Rating Update from a Top Analyst

Introduction

Company Name.
NRX Pharmaceuticals Inc.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
NRx Pharmaceuticals, Inc., a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned food and drug administration-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior. The company has a partnership with Alvogen Inc. and Lotus Pharmaceutical Company; development and manufacturing agreement with Nephron Pharmaceuticals, Inc. and Alcami; license agreement with Apkarian Technologies; development and license agreement with Glytech; license agreement with Sarah Herzog Memorial Hospital. The company was founded in 2015 and is based in Wilmington, Delaware.
Issue price:
--